Lantern Pharma (NASDAQ: LTRN) announced that the U.S. Food and Drug Administration raised no objections to proposed protocol amendments for the ongoing Phase 2 HARMONIC trial evaluating LP-300 in never-smokers with advanced non-small cell lung cancer adenocarcinoma. The company said the FDA's written response to its Type C meeting request provides a clearer regulatory path forward for the program, including a strategy focused on the EGFR exon 21 L858R-mutant never-smoker population, where emerging data suggest LP-300 may offer differentiated benefit in combination with standard chemotherapy following kinase inhibitor treatment failure.
The FDA's support is a significant milestone for Lantern Pharma, as it allows the company to refine its clinical development strategy for LP-300. By targeting a specific genetic mutation within the never-smoker population, Lantern aims to achieve more precise and effective treatment outcomes. This approach aligns with the broader trend in oncology toward precision medicine, where therapies are tailored to the genetic characteristics of individual tumors.
Lantern Pharma is a clinical-stage precision oncology company that leverages artificial intelligence and machine learning through its proprietary RADR platform to transform the development of cancer therapies. The company's pipeline includes several promising candidates, such as LP-184, LP-284, and LP-300, which is the focus of the HARMONIC trial. Additionally, Lantern has made its multi-agentic AI co-scientist platform, withZeta.ai, commercially available as a subscription-based research platform, representing a new revenue stream.
The HARMONIC trial is evaluating LP-300 in never-smoker patients with relapsed advanced lung adenocarcinoma following tyrosine kinase inhibitor treatment. The FDA's no-objection letter provides a clearer regulatory pathway, which could accelerate the development and potential approval of LP-300. This development is particularly important for never-smokers with lung cancer, a population that often has distinct genetic profiles and may respond differently to standard treatments.
Lantern Pharma operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas. The company continues to focus on developing innovative therapies for cancer patients, leveraging its AI platform to identify biomarkers and optimize clinical trial designs. The FDA's support for the HARMONIC trial amendments underscores the potential of Lantern's approach to precision oncology.
For more information, visit the company's newsroom at https://ibn.fm/LTRN. The full press release is available at https://ibn.fm/Rxklm.
